JP2021530456A5 - - Google Patents

Info

Publication number
JP2021530456A5
JP2021530456A5 JP2020572517A JP2020572517A JP2021530456A5 JP 2021530456 A5 JP2021530456 A5 JP 2021530456A5 JP 2020572517 A JP2020572517 A JP 2020572517A JP 2020572517 A JP2020572517 A JP 2020572517A JP 2021530456 A5 JP2021530456 A5 JP 2021530456A5
Authority
JP
Japan
Prior art keywords
crystalline salt
pharmaceutical composition
salt according
subject
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020572517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040276 external-priority patent/WO2020010068A1/en
Publication of JP2021530456A publication Critical patent/JP2021530456A/ja
Publication of JP2021530456A5 publication Critical patent/JP2021530456A5/ja
Priority to JP2024076310A priority Critical patent/JP2024105460A/ja
Pending legal-status Critical Current

Links

JP2020572517A 2018-07-02 2019-07-02 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態 Pending JP2021530456A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076310A JP2024105460A (ja) 2018-07-02 2024-05-09 2-(3,5-ジクロロ-4-((5-イソプロピル-6-オキソ-1,6-ジヒドロピリダジン-3-イル)オキシ)フェニル)-3,5-ジオキソ-2,3,4,5-テトラヒドロ-1,2,4-トリアジン-6-カルボニトリルの固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692914P 2018-07-02 2018-07-02
US62/692,914 2018-07-02
PCT/US2019/040276 WO2020010068A1 (en) 2018-07-02 2019-07-02 Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076310A Division JP2024105460A (ja) 2018-07-02 2024-05-09 2-(3,5-ジクロロ-4-((5-イソプロピル-6-オキソ-1,6-ジヒドロピリダジン-3-イル)オキシ)フェニル)-3,5-ジオキソ-2,3,4,5-テトラヒドロ-1,2,4-トリアジン-6-カルボニトリルの固体形態

Publications (2)

Publication Number Publication Date
JP2021530456A JP2021530456A (ja) 2021-11-11
JP2021530456A5 true JP2021530456A5 (cg-RX-API-DMAC10.html) 2022-07-08

Family

ID=67441642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572517A Pending JP2021530456A (ja) 2018-07-02 2019-07-02 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態
JP2024076310A Pending JP2024105460A (ja) 2018-07-02 2024-05-09 2-(3,5-ジクロロ-4-((5-イソプロピル-6-オキソ-1,6-ジヒドロピリダジン-3-イル)オキシ)フェニル)-3,5-ジオキソ-2,3,4,5-テトラヒドロ-1,2,4-トリアジン-6-カルボニトリルの固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076310A Pending JP2024105460A (ja) 2018-07-02 2024-05-09 2-(3,5-ジクロロ-4-((5-イソプロピル-6-オキソ-1,6-ジヒドロピリダジン-3-イル)オキシ)フェニル)-3,5-ジオキソ-2,3,4,5-テトラヒドロ-1,2,4-トリアジン-6-カルボニトリルの固体形態

Country Status (12)

Country Link
US (3) US20210122740A1 (cg-RX-API-DMAC10.html)
EP (2) EP3818057A1 (cg-RX-API-DMAC10.html)
JP (2) JP2021530456A (cg-RX-API-DMAC10.html)
KR (2) KR20250167140A (cg-RX-API-DMAC10.html)
CN (1) CN112638904A (cg-RX-API-DMAC10.html)
AR (1) AR115666A1 (cg-RX-API-DMAC10.html)
AU (2) AU2019298236A1 (cg-RX-API-DMAC10.html)
CA (1) CA3104860A1 (cg-RX-API-DMAC10.html)
IL (2) IL321116A (cg-RX-API-DMAC10.html)
MX (3) MX2021000107A (cg-RX-API-DMAC10.html)
TW (2) TW202615431A (cg-RX-API-DMAC10.html)
WO (1) WO2020010068A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
KR20230066408A (ko) 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
US12616701B2 (en) 2020-10-19 2026-05-05 Assia Chemical Industries Ltd Solid state forms of Resmetirom
WO2022165227A1 (en) * 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
US20240218009A1 (en) * 2021-04-21 2024-07-04 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
TW202337470A (zh) 2021-09-27 2023-10-01 美商瑪德瑞高製藥公司 用於縮減肝臟體積之瑞美替隆
MX2024005647A (es) * 2021-11-11 2024-05-24 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
JP2026521649A (ja) 2023-06-22 2026-06-30 マドリガル ファーマシューティカルズ インコーポレイテッド THR-βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
EP4762048A2 (en) 2023-10-16 2026-06-24 Cipla Limited Resmetirom polymorphs and process for their preparation
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025172958A1 (en) * 2024-02-16 2025-08-21 Metrochem Api Pvt Ltd Solid state forms of resmetirom
WO2025231587A1 (zh) * 2024-05-06 2025-11-13 杭州科巢生物科技有限公司 一种瑞司美替罗无水晶型ch及其制备方法
WO2026067708A1 (zh) * 2024-09-30 2026-04-02 齐鲁制药有限公司 瑞司美替罗晶型及其制备方法和用途
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom
WO2026107045A1 (en) 2024-11-12 2026-05-21 Madrigal Pharmaceuticals, Inc. Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
ATE480524T1 (de) * 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
ES2795450T3 (es) * 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
MX394463B (es) * 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
US12616701B2 (en) * 2020-10-19 2026-05-05 Assia Chemical Industries Ltd Solid state forms of Resmetirom

Similar Documents

Publication Publication Date Title
US20250368626A1 (en) Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile
JP2021183628A (ja) カルビドパおよびl−ドーパプロドラッグならびにそれらの使用方法
JP4354984B2 (ja) 水溶性ストロンチウム塩を用いる軟骨/骨症状の治療
JP2024105460A5 (cg-RX-API-DMAC10.html)
CA2716860C (en) Compounds and method for reducing uric acid
AU2011281923B2 (en) Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
KR100273888B1 (ko) 2,2-디클로로알칸카르복실산,그의제조방법,그를함유하는약물,및그의내인슐린치료용용도
JP2020512316A5 (cg-RX-API-DMAC10.html)
TWI303634B (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,4']bipyridinyl in pure crystalline form, process for synthesis, and pharmaceutical composition containing the same
JP2023036708A5 (cg-RX-API-DMAC10.html)
CN103228618B (zh) 新化合物及其医药用途
JP2023109937A5 (cg-RX-API-DMAC10.html)
JP2010519300A5 (cg-RX-API-DMAC10.html)
JP2019516749A5 (cg-RX-API-DMAC10.html)
JP6404358B2 (ja) マルトール第二鉄の結晶形態
US8916609B2 (en) Compounds as L-cystine crystallization inhibitors and uses thereof
RU2009104346A (ru) Ксинафоатная соль замещенного 5-оксазол-2-ил-хинолинового соединения
JP5069690B2 (ja) 酸と第四級アンモニウムとの塩を調製するための新規な方法
KR20130095735A (ko) 테노포비어 디소프록실 푸마레이트의 결정
RU2021132455A (ru) Новые твердые формы (2s,3s,4s,5r,6s)-3,4,5-тригидрокси-6-(((4ar,10ar)-7-гидрокси-1-пропил-1,2,3,4,4a,5,10,10a-октагидробензо[g]хинолин-6-ил)окси)тетрагидро-2h-пиран-2-карбоновой кислоты
US8859824B2 (en) Dual cation dual anion coordination complexes
RU2026106261A (ru) Полиморфы и содержащие их композиции
WO2020230876A1 (ja) N-(2-エチルスルホニルアミノ-5-トリフルオロメチル-3-ピリジル)シクロヘキサンカルボキサミド・一ナトリウム塩の無水和物結晶体
CN102036714A (zh) 晶体2-((2s,3r,4e,6e,10e,12s)-13-(4-氟苯氧基)-2,3,12-三羟基十三碳-4,6,10-三烯-8-炔)氧基)乙酸的无水形式和水合物形式
RU2474577C3 (ru) Кристаллические формы 3-[5-(2-фторфенил)-[1,2,4]оксадиазол-3-ил]бензойной кислоты, их применение и способы получения